This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Zacks.com featured highlights JAKKS Pacific, Green Dot, Signet Jewelers, Gibraltar Industries and Pfizer
by Zacks Equity Research
JAKK, GDOT, SIG, ROCK, and PFE offer low P/S ratios and high growth potential, making them standout value plays now.
PFEPositive Net Change JAKKNegative Net Change SIGPositive Net Change GDOTPositive Net Change ROCKPositive Net Change
pharmaceuticals
Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?
by Zacks Equity Research
ZTS jumps 13% in a month as strong new product sales, strategic deals, and rising earnings estimates boost investor confidence.
BAYRYPositive Net Change LXRXNegative Net Change AMRNPositive Net Change ZTSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
by Zacks Equity Research
LYRA skyrockets 356% after its lead nasal implant, LYR-210, meets key goals in a pivotal phase III chronic rhinosinusitis study.
BAYRYPositive Net Change LXRXNegative Net Change AMRNPositive Net Change LYRANegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector
by Zacks Equity Research
With FDA platform technology designation for its viral vector, SRPT can fast-track other therapies using the same gene-delivery method.
RHHBYPositive Net Change SRPTPositive Net Change AGENPositive Net Change IMCRPositive Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
by Zacks Equity Research
REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.
REGNPositive Net Change SNYPositive Net Change NVOPositive Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer
by Zacks Equity Research
Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong phase III data.
JNJPositive Net Change BAYRYPositive Net Change LXRXNegative Net Change AMRNPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout
by Zacks Equity Research
MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.
SNYPositive Net Change BMYPositive Net Change MRKPositive Net Change MLTXNegative Net Change
biotechs medical pharmaceuticals
SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease
by Zacks Equity Research
Sanofi's rilzabrutinib earns its fourth orphan drug status from the FDA, this time targeting sickle cell disease.
SNYPositive Net Change BAYRYPositive Net Change LXRXNegative Net Change AMRNPositive Net Change
biotechnology biotechs medical pharmaceuticals
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
by Urmimala Biswas
BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.
BSXNegative Net Change AMGNPositive Net Change DXCMNegative Net Change ABBVPositive Net Change CTRENegative Net Change CHCTPositive Net Change
biotechnology biotechs healthcare medical medical-devices pharmaceuticals
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell?
by Zacks Equity Research
EXEL gains 28.2% YTD, driven by Cabometyx growth, pipeline progress and an increase in stock buyback authorizations.
BMYPositive Net Change MRKPositive Net Change EXELNegative Net Change
biotechnology biotechs medical pharmaceuticals
Zacks.com featured highlights StoneCo, Centene, CVS Health and Pfizer
by Zacks Equity Research
StoneCo, Centene, CVS, and Pfizer stand out as top value picks with strong cash flow amid market uncertainty.
PFEPositive Net Change CVSPositive Net Change CNCPositive Net Change STNEPositive Net Change
pharmaceuticals
Moderna Secures FDA Nod for Next-Gen COVID-19 Vaccine mNexspike
by Zacks Equity Research
MRNA wins FDA approval for mNexspike, a fridge-stable COVID shot, but with a narrower use label than it sought.
PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Bristol Myers Collaborates With BNTX for Oncology Candidate
by Zacks Equity Research
BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid tumors.
NVSPositive Net Change BMYPositive Net Change PFEPositive Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
by Zacks Equity Research
KYMR jumps after KT-621 phase I data beats expectations, matching or topping Dupixent on key biomarkers in Th2 diseases.
SNYPositive Net Change LXRXNegative Net Change AMRNPositive Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III
by Zacks Equity Research
AMGN's Imdelltra slashes lung cancer death risk by 40% in Phase III, extending survival by over five months compared to chemotherapy.
AMGNPositive Net Change BAYRYPositive Net Change LXRXNegative Net Change AMRNPositive Net Change
biotechnology biotechs medical pharmaceuticals
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
by Zacks Equity Research
SNY's $9.5 billion deal to acquire BPMC boosts its immunology pipeline and adds fast-growing Ayvakit to its portfolio.
SNYPositive Net Change BAYRYPositive Net Change AMRNPositive Net Change BPMCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results
by Zacks Equity Research
SMMT plunges 31% as its NSCLC drug shows strong PFS but misses statistical significance on survival data.
MRKPositive Net Change SMMTNegative Net Change TILPositive Net Change BNTXPositive Net Change
biotechs medical pharmaceuticals
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study
by Zacks Equity Research
Merck reports promising response rates for its ADC zilovertamab vedotin in relapsed DLBCL and KRAS inhibitor MK-1084 in solid tumors.
MRKPositive Net Change LXRXNegative Net Change CMMBNo Net Change
pharmaceuticals
Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study
by Zacks Equity Research
GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard care.
NVSPositive Net Change PFEPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Zacks.com featured highlights Novartis, ENGIE, MasTec, Dorman Products and Sterling Infrastructure
by Zacks Equity Research
NVS, ENGIY, MTZ, DORM, and STRL stand out as low-leverage stocks to help investors weather market volatility with confidence.
NVSPositive Net Change STRLNegative Net Change MTZNegative Net Change DORMPositive Net Change ENGIYPositive Net Change
pharmaceuticals
Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?
by Ekta Bagri
GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However, we recommend investors remain on the sidelines at current levels.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies
by Zacks Equity Research
Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pharma Stock Roundup: LLY's New Deal, GSK & SNY's Pipeline Updates
by Kinjel Shah
LLY to acquire SiteOne for up to $1 billion. GSK's antibiotic study ends early for efficacy. MRNA loses H5 flu vaccine funding, while SNY sees mixed COPD data.
SNYPositive Net Change GSKPositive Net Change MRKPositive Net Change LLYNegative Net Change MRNAPositive Net Change
pharmaceuticals
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
by Zacks Equity Research
Immunovant stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
BAYRYPositive Net Change LXRXNegative Net Change AMRNPositive Net Change IMVTPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
The Zacks Analyst Blog Highlights Berkshire Hathaway, AbbVie, Intuitive Surgical, Hamilton Beach Brands and AXIL Brands
by Zacks Equity Research
Zacks highlights strong showings from ABBV, ISRG, HBB and AXIL, while BRK.B gains on insurance growth and capital strength despite headwinds.
ISRGNegative Net Change BRK.BPositive Net Change ABBVPositive Net Change HBBPositive Net Change AXILNegative Net Change
pharmaceuticals